Medical Device | March 22, 2022
Thermo Fisher Scientific to showcase global innovation at DCAT Week 2022
Expanded capabilities across pharma services network accelerate innovation and enhance productivity for customers
Expanded capabilities across pharma services network accelerate innovation and enhance productivity for customers
Allogeneic discogenic cell therapy was well tolerated and produced clinically meaningful, statistically significant improvements in low back pain, function, and quality of life by 12 weeks following intradiscal injection
Data from the Phase 2b QUASAR Induction Study showed approximately 60% of patients achieved the primary endpoint of clinical response, and approximately 30% showed endoscopic improvement with TREMFYA treatment compared with placebo
It’s the company’s fourth manufacturing site worldwide. Others are located in the US, UK and China
Subscribe To Our Newsletter & Stay Updated
